

Presidio Pharmaceuticals Announces Relocation of Corporate Headquarters to Mission Bay, San Francisco

San Francisco, CA – December 5, 2007 – Presidio Pharmaceuticals, Inc. announced today that it has relocated its corporate headquarters to San Francisco's Mission Bay campus.

The new headquarters, located at 1700 Owens Street in San Francisco's Mission Bay District, is within a new office/lab complex developed by Alexandria Real Estate Equities. It will house the company's research, clinical development and administrative operations. Presidio's new site will accommodate the growth in staffing and operations necessary to support the company's development programs in HIV and hepatitis.

"San Francisco proudly welcomes Presidio Pharmaceuticals to the Mission Bay neighborhood," said Mayor Gavin Newsom. "I am pleased to see another leading-edge company join the City's growing biotechnology community in Mission Bay, supporting San Francisco's commitment to innovation and emerging industries."

The Mission Bay life sciences campus is being developed by Alexandria in partnership with the University of California and the City of San Francisco. Said Presidio's President and CEO, Omar K. Haffar, "We're pleased to be working with Alexandria, a real estate developer with extensive expertise in the needs of pharmaceutical development companies. Their partnership with the City of San Francisco and UCSF has enabled a great life sciences campus that allows us to rapidly expand our operations."

Alexandria is delighted to welcome a promising early-stage life science company to its iconic office/laboratory facility in Mission Bay. Stephen A. Richardson, Alexandria's Senior Vice President – San Francisco Bay Area states, "The addition of Presidio Pharmaceuticals substantially fulfills the vision of this facility as a world-class platform for a wide range of life science companies seeking to accelerate their drug discovery efforts in one of the most vibrant and innovative clusters in the United States. We anticipate a mutually beneficial partnership and look forward to supporting Presidio's success."

The effective date of the move is December 3, 2007.

Presidio Pharmaceuticals, Inc.
1700 Owens Street, Suite 585
San Francisco, CA 94158

About Presidio Pharmaceuticals, Inc:

Presidio Pharmaceuticals, Inc is a specialty pharmaceutical company focused on discovering, in-licensing, developing and commercializing novel therapeutics for viral infections, including but not limited to HIV-1 and HCV. Presidio has raised over \$27 million in financing from Panorama Capital (formerly JP Morgan Partners), Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures. For more information, please visit our website at www.presidiopharma.com

Contact:

Antoun A. Nabhan

antoun@presidiopharma.com

415-655-7562